drugset / Trial / NCT05174156
Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer
Phase 2
Unknown
50 enrolled
Sixth Affiliated Hospital, Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd. · collabNanjing Geneseeq Technology Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study intends to explore the predictive biomarkers by Next-generation sequencing (NGS) and multiple immunohistochemistry (mIHC) for the treatment of SHR-1210 in combination with paclitaxel and platinum in advanced esophageal cancer.
Timeline
- Start
- 2022-01-01
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |